CASE REPORT article

Front. Oncol.

Sec. Genitourinary Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1581452

This article is part of the Research TopicUrothelial Neoplasms: An Integrated Approach to Prevention, Diagnostics, and Personalized TherapyView all 5 articles

Toripalimab treatment of bladder-preserving therapy for locally advanced bladder cancer:a case report

Provisionally accepted
Zhiyun  YangZhiyun Yang1YIdao  LiuYIdao Liu1Ji  LiJi Li1Xingsheng  WangXingsheng Wang2Jiafu  JiangJiafu Jiang1Jun  PanJun Pan1Xingming  ZhangXingming Zhang3*
  • 1Department of Urology, Dehong Prefecture People's Hospital, Dehong, China
  • 2德宏州人民医院麻醉科, Dehong, China
  • 3Department of Urology, West China Hospital, Sichuan University, Chendu, China

The final, formatted version of the article will be published soon.

Neoadjuvant chemotherapy and radical cystectomy is the standard treatment for muscle invasive bladder cancer. For patients who are intolerant or unwilling to receive radical surgery and chemotherapy, the use of immune therapy combined with bladder preservation treatment has gradually become a viable treatment option. In this article, We aimed to present a case of cT2N0M0 Bladder cancer patient who was intolerant to chemotherapy and was treated with Toripalimab as a single-agent bladder preservation therapy for three cycles. After 15 months of treatment, a clinical complete response (cCR) was achieved, thus retaining the bladder. In this report, the safety profile of Toripalimab was favorable, with no severe or uncontrollable adverse p 删除[苏玉玲]:events. The patient's pathological IHC showed PD-L1 negative (TPS <1%, CPS <1%) and did not undergo mTURBT, which is a rare phenomenon. Our report suggests that Patients with PD-L1 negative but CD8+ T cell positive tumor infiltration can also benefit from PD-L1 inhibitor treatment and even achieve cCR to preserve the bladder.

Keywords: Muscle-invasive bladder cancer, Bladder-preserving therapy, immune therapy, Toripalimab, PD-L1, CD8+ T lymphocytes

Received: 22 Feb 2025; Accepted: 30 May 2025.

Copyright: © 2025 Yang, Liu, Li, Wang, Jiang, Pan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xingming Zhang, Department of Urology, West China Hospital, Sichuan University, Chendu, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.